Literature DB >> 7640154

Absorption of clonazepam after intranasal and buccal administration.

M W Schols-Hendriks1, J J Lohman, R Janknegt, J J Korten, F W Merkus, P M Hooymans.   

Abstract

Serum concentrations of clonazepam after intranasal, buccal and intravenous administration were compared in a cross-over study in seven healthy male volunteers. Each subject received a 1.0 mg dose of clonazepam intranasally and buccally and 0.5 mg intravenously. A Cmax of 6.3 +/- 1.0 ng ml-1 (mean; +/- s.d.) was measured 17.5 min (median) (range 15-20 min) after intranasal administration. A second peak (4.6 +/- 1.3 ng ml-1) caused by oral absorption was seen after 1.7 h (range 0.7-3.0 h). After buccal administration a Cmax of 6.0 +/- 3.0 ng ml-1 was measured after 50 min (range 30-90 min) with a second peak of 6.5 +/- 2.5 ng ml-1 after 3.0 h (range 2.0-4.0 h). Two minutes after i.v. injection of 0.5 mg clonazepam the serum concentration was 27 +/- 18 ng ml-1. It is concluded that intranasal clonazepam is an alternative to buccal administration. However, the Cmax of clonazepam after intranasal administration is not high enough to recommend the intranasal route as an alternative to intravenous injection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7640154      PMCID: PMC1365135          DOI: 10.1111/j.1365-2125.1995.tb04476.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  3 in total

1.  Clonazepam: a review of its pharmacological properties and therapeutic efficacy in epilepsy.

Authors:  R M Pinder; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1976-11       Impact factor: 9.546

2.  Nasal absorption enhancement of 17 beta-estradiol by dimethyl-beta-cyclodextrin in rabbits and rats.

Authors:  W A Hermens; M J Deurloo; S G Romeyn; J C Verhoef; F W Merkus
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

3.  Plasma concentrations of clonazepam after single rectal administration.

Authors:  G W Rylance; J Poulton; R C Cherry; R E Cullen
Journal:  Arch Dis Child       Date:  1986-02       Impact factor: 3.791

  3 in total
  3 in total

Review 1.  Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.

Authors:  Hao Zhang; Jie Zhang; James B Streisand
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Intranasal delivery of antiepileptic medications for treatment of seizures.

Authors:  Daniel P Wermeling
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

3.  Antiepileptic drug treatment in the end-of-life phase of glioma patients: a feasibility study.

Authors:  Johan A F Koekkoek; Tjeerd J Postma; Jan J Heimans; Jaap C Reijneveld; Martin J B Taphoorn
Journal:  Support Care Cancer       Date:  2015-09-25       Impact factor: 3.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.